Brentuximab vedotin 50 MG Injection [Adcetris] — RxCUI 1147327
RxNorm drug concept · Semantic branded drug
RxCUI 1147327
Semantic branded drug · SBD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1147327
Official nameBrentuximab vedotin 50 MG Injection [Adcetris]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAdcetris 50 MG Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)2,394 prescriptions · 34 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Brentuximab Vedotin Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It treats several lymphomas, including classical Hodgkin lymphoma, systemic anaplastic large cell lymphoma, other CD30-positive T-cell lymphomas, some skin lymphomas, and relapsed...
- It is given through a vein as a 30-minute infusion by a healthcare professional, usually every 2 or 3 weeks. You do not take it at home. Your team decides the number of doses and m...
- Common ones include numbness or tingling in the hands and feet, nausea, tiredness, muscle aches, constipation or diarrhea, and fever. Tell your team about nerve symptoms early, bec...
- Call for fever or signs of infection, trouble breathing, severe stomach pain, severe skin rash or blistering, or signs of an allergic reaction. Also call about confusion, balance t...
🕸️ Concept Web — How Brentuximab vedotin 50 MG Injection [Adcetris] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Brentuximab vedotin 50 MG Injection [Adcetris]
RxCUI 1147327 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Brentuximab vedotin
1147320IN
-
Brentuximab vedotin
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Adcetris
1147324BN
-
Adcetris
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Brentuximab vedotin Injection
1655962SCDF -
Brentuximab vedotin Injectable Product
1163087SCDG -
Brentuximab vedotin Injection [Adcetris]
1655965SBDF -
Adcetris Injectable Product
1170611SBDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Brentuximab vedotin Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Brentuximab vedotin 50 MG Injection
1147323SCD -
Brentuximab vedotin 50 MG
1655961SCDC -
Brentuximab vedotin 50 MG [Adcetris]
1655964SBDC
-
Brentuximab vedotin 50 MG Injection
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Brentuximab vedotin 50 MG Injection
SCD · 1147323 -
Brentuximab vedotin 50 MG
SCDC · 1655961 -
Brentuximab vedotin Injection
SCDF · 1655962 -
Brentuximab vedotin Injectable Product
SCDG · 1163087
Brand-Name Concepts
-
Brentuximab vedotin 50 MG [Adcetris]
SBDC · 1655964 -
Brentuximab vedotin Injection [Adcetris]
SBDF · 1655965 -
Adcetris Injectable Product
SBDG · 1170611 -
Adcetris
BN · 1147324
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 1147327 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 51144-0050-01 | 1 VIAL, SINGLE-DOSE in 1 BOX (51144-050-01) / 10.5 mL in 1... | ADCETRIS | SEAGEN INC. | 2011-08-25 |
Observed labelers:
SEAGEN INC. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J9042 | Brentuximab vedotin inj | 1 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.